Your browser doesn't support javascript.
loading
Investigation of metabolism and disposition of GSK1322322, a peptidase deformylase inhibitor, in healthy humans using the entero-test for biliary sampling.
Mamaril-Fishman, Donna; Zhu, John; Lin, Min; Felgate, Clive; Jones, Lori; Stump, Patrick; Pierre, Esaie; Bowen, Chester; Naderer, Odin; Dumont, Etienne; Patel, Parul; Gorycki, Peter D; Wen, Bo; Chen, Liangfu; Deng, Yanli.
Afiliação
  • Mamaril-Fishman D; Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania (D.M.F., M.L., E.P., C.B., P.D.G., B.W., L.C., Y.D.) and Ware, United Kingdom (C.F.); Department of Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania (J.Z.);
  • Zhu J; Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania (D.M.F., M.L., E.P., C.B., P.D.G., B.W., L.C., Y.D.) and Ware, United Kingdom (C.F.); Department of Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania (J.Z.);
  • Lin M; Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania (D.M.F., M.L., E.P., C.B., P.D.G., B.W., L.C., Y.D.) and Ware, United Kingdom (C.F.); Department of Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania (J.Z.);
  • Felgate C; Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania (D.M.F., M.L., E.P., C.B., P.D.G., B.W., L.C., Y.D.) and Ware, United Kingdom (C.F.); Department of Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania (J.Z.);
  • Jones L; Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania (D.M.F., M.L., E.P., C.B., P.D.G., B.W., L.C., Y.D.) and Ware, United Kingdom (C.F.); Department of Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania (J.Z.);
  • Stump P; Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania (D.M.F., M.L., E.P., C.B., P.D.G., B.W., L.C., Y.D.) and Ware, United Kingdom (C.F.); Department of Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania (J.Z.);
  • Pierre E; Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania (D.M.F., M.L., E.P., C.B., P.D.G., B.W., L.C., Y.D.) and Ware, United Kingdom (C.F.); Department of Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania (J.Z.);
  • Bowen C; Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania (D.M.F., M.L., E.P., C.B., P.D.G., B.W., L.C., Y.D.) and Ware, United Kingdom (C.F.); Department of Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania (J.Z.);
  • Naderer O; Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania (D.M.F., M.L., E.P., C.B., P.D.G., B.W., L.C., Y.D.) and Ware, United Kingdom (C.F.); Department of Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania (J.Z.);
  • Dumont E; Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania (D.M.F., M.L., E.P., C.B., P.D.G., B.W., L.C., Y.D.) and Ware, United Kingdom (C.F.); Department of Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania (J.Z.);
  • Patel P; Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania (D.M.F., M.L., E.P., C.B., P.D.G., B.W., L.C., Y.D.) and Ware, United Kingdom (C.F.); Department of Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania (J.Z.);
  • Gorycki PD; Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania (D.M.F., M.L., E.P., C.B., P.D.G., B.W., L.C., Y.D.) and Ware, United Kingdom (C.F.); Department of Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania (J.Z.);
  • Wen B; Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania (D.M.F., M.L., E.P., C.B., P.D.G., B.W., L.C., Y.D.) and Ware, United Kingdom (C.F.); Department of Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania (J.Z.);
  • Chen L; Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania (D.M.F., M.L., E.P., C.B., P.D.G., B.W., L.C., Y.D.) and Ware, United Kingdom (C.F.); Department of Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania (J.Z.);
  • Deng Y; Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania (D.M.F., M.L., E.P., C.B., P.D.G., B.W., L.C., Y.D.) and Ware, United Kingdom (C.F.); Department of Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania (J.Z.);
Drug Metab Dispos ; 42(8): 1314-25, 2014 Aug.
Article em En | MEDLINE | ID: mdl-24872378
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Proteases / Bile / Compostos Bicíclicos Heterocíclicos com Pontes / Ácidos Hidroxâmicos Tipo de estudo: Clinical_trials Limite: Adult / Humans / Male / Middle aged Idioma: En Revista: Drug Metab Dispos Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Proteases / Bile / Compostos Bicíclicos Heterocíclicos com Pontes / Ácidos Hidroxâmicos Tipo de estudo: Clinical_trials Limite: Adult / Humans / Male / Middle aged Idioma: En Revista: Drug Metab Dispos Ano de publicação: 2014 Tipo de documento: Article